{"id":"adjuvant-tislelizumab-plus-lenvatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (e.g., hepatitis, pneumonitis)"},{"rate":null,"effect":"Proteinuria"}]},"_chembl":{"chemblId":"CHEMBL1289601","moleculeType":"Small molecule","molecularWeight":"426.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized anti-PD-1 monoclonal antibody that restores T-cell-mediated immune responses against cancer cells. Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling, reducing tumor vascularity and proliferation. The combination leverages immunotherapy with targeted anti-angiogenic therapy to enhance overall anti-tumor efficacy.","oneSentence":"Tislelizumab blocks PD-1 on immune cells to enhance anti-tumor immunity, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:41.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of hepatocellular carcinoma (Phase 3)"}]},"trialDetails":[{"nctId":"NCT05254847","phase":"PHASE2","title":"Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-02-24","conditions":"Biliary Tract Cancer","enrollment":65},{"nctId":"NCT06420440","phase":"PHASE2","title":"Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model","status":"RECRUITING","sponsor":"Chen Xiaoping","startDate":"2024-06-01","conditions":"HCC","enrollment":160},{"nctId":"NCT04615143","phase":"PHASE2","title":"Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Recurrent Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT05910970","phase":"PHASE3","title":"Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2024-02-15","conditions":"Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor","enrollment":200},{"nctId":"NCT06059885","phase":"PHASE2","title":"Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2021-12-22","conditions":"Liver Neoplasms","enrollment":60},{"nctId":"NCT05807776","phase":"PHASE2","title":"Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-01","conditions":"Resectable Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05620498","phase":"PHASE2","title":"Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-08","conditions":"Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant tislelizumab plus lenvatinib","genericName":"Adjuvant tislelizumab plus lenvatinib","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab blocks PD-1 on immune cells to enhance anti-tumor immunity, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth. Used for Adjuvant treatment of hepatocellular carcinoma (Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}